Quanterix Corporation Releases Operating Results for First Quarter 2019
64% Q1 revenue growth and 650 bps gross margin improvement LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis…
Pharmaceuticals, Biotechnology and Life Sciences
64% Q1 revenue growth and 650 bps gross margin improvement LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis…
DUBLIN–(BUSINESS WIRE)–The “Global Bone Cancer Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. Small and medium sized pharmaceutical…
Due to an increase in the incidence of medical ailments, the marketstudied is expected to grow over the forecast period.
Second Launch@Shares Competition Announced in Collaboration withMTTC/MALSI Conference and MassBio’s MassCONNECT Program
63% seek competitive advantage by adding digital features to products or offering new digital solutions BOSTON–(BUSINESS WIRE)–Digital know-how is decisive…
BioLegend Campus Inauguration Symposium focused on Cancer Immunotherapy features Nobel Laureate and World-Renowned Immunologists SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biolegend?src=hash" target="_blank"gt;#biolegendlt;/agt;–BioLegend, leading…
DUBLIN–(BUSINESS WIRE)–The “Analytical Report for Healthcare Licensing with focus on Transplant” report has been added to ResearchAndMarkets.com’s offering. Transplantation gives…
The global food enzymes market is expected to grow at a CAGR of 7.5%from 2019 to reach $3,125.1 million by 2024 from $2,176.9 million in2019.
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
Demand for combination therapies for the treatment of respiratorydiseases has been on an increasing spree